Educational Videos

Estimated time to complete activity: 1 hour 30 minutes

Compatible with all modern internet browsers and mobile devices

EDUCATIONAL OBJECTIVES

• To review the pathophysiology of SpA and the role of IL-17A and IL-17F therein

• Provide an overview of the latest data for IL-17A and IL-17A/F dual inhibitors and explore the role they play in treating SpA

• To consider the clinical implications of the foregoing for practicing clinicians

TARGET AUDIENCE

This activity is designed for qualified rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with inflammatory diseases.

PROGRAMME OVERVIEW

In this webinar, IL-17 Inhibition: Controlling inflammation and disease progression in SpA, experts discuss the pathophysiology of SpA, and the role of IL-17A and IL-17F. the role of IL-17A and IL-17A/F dual inhibitors in the management of axSpA, alongside the role of IL-17A and IL-17A/F dual inhibitors in the management of PsA. This is followed by an interactive Q&A session between the audience and our panel of industry experts.

DISCLOSURE OF CONFLICTS OF INTEREST

CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.